Ariad
Takeda to acquire Ariad in $5.2 billion deal
January 9, 2017Manufacturing and Production, Sales and Marketing Ariad, Takeda
Takeda has acquired US drug maker, Ariad Pharmaceuticals, in a deal worth $5.2 billion. Takeda has been looking to bolster …
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
Ariad names Manmeet Soni CFO
March 14, 2016Business Services, Sales and Marketing Ariad, CEO, appointment, boardroom, cfo
Ariad Pharmaceuticals Inc (Nasdaq: ARIA) named Manmeet Soni chief financial officer, effective March 21, 2016, succeeding Edward Fitzgerald. Mr Soni will …
Ariad names EMD Serono’s Paris Panayiotopoulos as new president and chief exec
December 21, 2015Sales and Marketing Ariad, Ariad Pharmaceuticals, EMD Serono, Paris Panayiotopoulos, harvey Berger
The board of directors at Ariad Pharmaceuticals has appointed Paris Panayiotopoulos as president and chief executive from 1 January 2016. …
Ariad founder retires
May 11, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ariad, harvey Berger
Dr Harvey Berger the founder of US pharma firm Ariad Pharmaceuticals has announced his decision to retire as chairman and …
EMA keeps Ariad cancer drug on the market
October 13, 2014Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib
The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …
EMA in new Iclusig probe
December 9, 2013Sales and Marketing Ariad, EMA, iclusig, leukaemia
Europe’s medicines regulator has begun a new review of Ariad Pharmaceuticals’ leukaemia drug Iclusig, looking in particular at the risk …
Ariad cancer drug pulled amid safety fears
November 1, 2013Sales and Marketing Ariad, FDA, iclusig, leukaemia
Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …
Ariad ditches CML trial
October 21, 2013Research and Development, Sales and Marketing Ariad, CML, iclusig
Ariad Pharmaceuticals has ditched its late-stage trial of Iclusig in patients with newly-diagnosed chronic myeloid leukemia (CML) after blood clots …
Ariad expands in Europe
February 22, 2013Sales and Marketing Ariad, leukaemia, leukemia
The new European boss of Ariad Pharmaceuticals has sketched out the US firm’s plans for its next-generation leukaemia drug, which …
Ariad files new blood cancer drug with the FDA
July 31, 2012Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer
Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …
Ariad touts next generation CML treatment
June 29, 2012Research and Development, Sales and Marketing Ariad, CML, Cancer, Europe, Switzerland
Ariad Pharmaceuticals is to expand into Europe following promising results for an investigational cancer drug. The US biotech firm will …
